Beijing, Aug 28, 2026 — China’s National Medical Products Administration (NMPA) suspended sales and use of two batches of Pierre Fabre Medicament’s Encorafenib capsules after a remote inspection found the French drugmaker used an unapproved active pharmaceutical ingredient process change in production and released the product to the Chinese market despite serious quality management deviations.
Regulatory Snapshot
| Attribute | Detail |
|---|---|
| Issuer | National Medical Products Administration (NMPA) |
| Announcement | 2026 No. 81 |
| Target company | Pierre Fabre Medicament (France) |
| Product | Encorafenib Capsules (国药准字HJ20250082) |
| Affected batches | 5G2T3, 5G2T4 |
| Manufacturing sites | 14 Schoolhouse Road, Somerset, NJ, USA; Site Progipharm, rue du Lycée, 45500 Gien, France |
| Inspection type | Remote inspection |
| Violation | Unapproved API process change; serious GMP deviation in change control and release review |
| Legal basis | Drug Administration Law, Article 99; Provisions for Overseas Inspections of Drugs and Medical Devices, Article 30 |
| Effective date | Immediate |
Violation Details
The NMPA said its remote review determined that Pierre Fabre had implemented a significant manufacturing process change for the Encorafenib API without obtaining regulatory approval. The company nonetheless used the modified API to produce batches 5G2T3 and 5G2T4, subsequently releasing them for sale in China. Regulators found that the firm’s change-control procedures and batch-release review processes seriously deviated from China’s Good Manufacturing Practice standards (2010 revision) and associated annexes, failing to meet statutory quality system requirements.
Market Impact Analysis
The suspension immediately blocks distribution of the two Encorafenib batches in China, where the BRAF inhibitor is used in oncology protocols, notably for metastatic colorectal cancer with BRAF V600E mutations. For Pierre Fabre, the enforcement action threatens its commercial standing in a key emerging market and raises questions about global change-control governance, given that the API modification appears to have been implemented across manufacturing sites in both the United States and France.
The case marks a significant use of remote inspection authority under Article 99 of the Drug Administration Law, signaling that the NMPA is prepared to invoke market suspension powers based on procedural and quality-system lapses without waiting for confirmed clinical adverse events. The dual-site manufacturing footprint—spanning New Jersey and Gien—suggests the unapproved process change may have broader implications beyond the two flagged batches, potentially triggering portfolio-wide scrutiny.
Forward-Looking Statement
Industry analysts expect Pierre Fabre to face a lengthy remediation process requiring submission of a formal API process change application, completion of supplementary validation studies, and a re-inspection before the suspension can be lifted. The NMPA’s reliance on remote inspection technology to detect the deviation underscores the growing effectiveness of China’s overseas oversight regime, potentially encouraging similar actions against other multinational drugmakers with manufacturing discrepancies. Oncology treatment centers in China may need to source alternative BRAF inhibitor therapies or draw from unaffected inventory batches while the two suspended lots are quarantined and recalled. The case is likely to prompt multinational pharmaceutical companies to audit their global change-control matrices against Chinese GMP requirements more rigorously, particularly for products manufactured across multiple international sites.-China Health Reform Pulse
Policy Source: https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260826174000158.html